Presillion stent
DeviceCenters will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
NCT Number: NCT00968019
The purpose of this study is: To evaluate the safety and performance of the Presillion stent in routine clinical practice.
Looking for future studies?
Notify MeAll sexes
Observational
Hospital Garcia Da Orta, Almada, Portugal
Primary endpoint: Composite of Major Adverse Cardiac Events (MACE), which includes cardiac death, myocardial infarction (Q-wave and non Q-wave) and clinically driven target lesion revascularization (TLR) at 12 months follow-up.
Data will be collected on 400 patients (from 14 hospitals in Spain and Portugal) treated with the Presillion stent in up to 2 de novo native coronary artery lesions
Study design: multicenter, prospective, observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
Time frame: at 12 months follow-up
Major adverse cardiac and cerebral events are defined as an adjudicated composite of cardiac death, myocardial infarction (Q-wave and non Q-wave), emergent coronary artery bypass surgery and target vessel revascularization (TVR).
The primary safety measure was the composite of MACE up to 12 months follow up. In order to show the safety of the device, the MACE rate was compared with the performance goal for bare metal stents(experience with bare metal stents in clinical trials suggested that the 12 month MACE rate should be about 25.0%).
Time frame: Peri-procedure up to discharge
Device success defined as achievement of a final diameter stenosis of <50% (by visual estimate), using the assigned device only
Time frame: Peri-procedure up to discharge
Lesion success defined as the attainment of <50% final diameter stenosis (by visual estimate) using any percutaneous method.
Time frame: Peri-procedure up to discharge
Procedural success defined as achievement of a final diameter stenosis of <50% (by visual estimate) using any percutaneous method, without the occurrence of death, MI (Myocardial Infarction), or repeat revascularization of the target lesion during the hospital stay
Time frame: Up to 30 days
Target Lesion Revascularization (TLR) is defined as any clinically-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel
Time frame: Up to 30 days
Target vessel revascularization (TVR) is defined as any clinically driven (as defined for TLR) repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.
Time frame: Up to 30 days
Target vessel failure includes any target vessel revascularization as well as any MI or any cardiac death that cannot be clearly attributed to a non-target vessel.
Target vessel failure will be reported when:
Time frame: Up to 30 days
A positive diagnosis of myocardial infarction is made when one of the following criteria is met:
Time frame: Up to 30 days
Time frame: Up to 30 days
Time frame: Up to 30 days
Thrombosis is defined as the formation of blood clot derived from aggregation of red cells or platelets obstructing the lumen of the vessel.
Time frame: up to 12 months
Target Lesion Revascularization (TLR) is defined as any clinically-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel
Time frame: Up to 12 months
Target vessel revascularization (TVR) is defined as any clinically driven (as defined for TLR) repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.
Time frame: Up to 12 months
Target vessel failure includes any target vessel revascularization as well as any MI or any cardiac death that cannot be clearly attributed to a non-target vessel.
Target vessel failure will be reported when:
Time frame: Up to 12 months
A positive diagnosis of myocardial infarction is made when one of the following criteria is met:
Time frame: Up to 12 months
Time frame: Up to 12 months
Thrombosis is defined as the formation of blood clot derived from aggregation of red cells or platelets obstructing the lumen of the vessel.
Time frame: Up to 12 months
Johnson and Johnson, S.A.
Industry
A Multicenter Postmarket Surveillance Registry Evaluating the Performance and Long Term Safety of the Presillion Stent in de Novo Native Coronary Artery Lesions. Iberian Registry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06299735
Arterial Occlusive Diseases, Arteriosclerosis
Ankara, Çankaya, Turkey (Türkiye)
View Trial DetailsNCT01777503
Acute Coronary Syndrome, Arterial Occlusive Diseases
Reggio Emilia, Italy
View Trial DetailsNCT00129038
Arterial Occlusive Diseases, Arteriosclerosis
Dublin, Ireland
View Trial DetailsNCT00357955
Arterial Occlusive Diseases, Arteriosclerosis
Providence, Rhode Island, United States
View Trial Details